Observations on Critical Path Project's fifth anniversary. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Observations on Critical Path Project's fifth anniversary. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Crit Path AIDS Proj. 1994-95 Winter;(No 30):2, 4. Unique Identifier : AIDSLINE AIDS/95700004
Kuromiya K

Abstract: Treatment activism, unknown five years ago, has been an important development of the AIDS epidemic. Activist pressure has pushed the government into greatly reducing the time taken to bring experimental treatments to market. For the first time in history, representatives of community-based organizations sit on scientific core committees and panels overseeing AIDS research. This activism must continue. While distrust of the political process and government runs deep among people with AIDS, particularly in communities of color, people with AIDS need to work with the research and drug development establishment so that experimental drugs under development reach communities that need them the most. The Federal government has never made treatment information easy to access. Therefore, activists and advocates need to continue their efforts to provide life-saving and life-extending information in treatment newsletters and fact sheets, community forums, treatment hotlines, and online communication networks.
Keywords: *Acquired Immunodeficiency Syndrome Civil Rights Clinical Trials Health Policy/*TRENDS *Patient Advocacy Public Health United States NEWSLETTER ARTICLEKWDacquiredimmunodeficiencysyndromecivilrightsclinicaltrialshealthpolicy/KWDtrendsKWDpatientadvocacypublichealthunitedstatesnewsletterarticle
950430
M9541108

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .